{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:36:35Z","timestamp":1793864195179,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1997,10,1]],"date-time":"1997-10-01T00:00:00Z","timestamp":875664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1997,10,1]],"date-time":"1997-10-01T00:00:00Z","timestamp":875664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[1997,10]]},"DOI":"10.1023\/a:1005805907311","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T23:56:21Z","timestamp":1040514981000},"page":"47-53","source":"Crossref","is-referenced-by-count":174,"title":["Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing"],"prefix":"10.1007","volume":"35","author":[{"given":"Peter a.","family":"Forsyth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casilda","family":"Balmaceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Brasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Deangelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"133993_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","volume":"111","author":"WP McGuire","year":"1989","unstructured":"McGuire WP, Rowinsky EK, Rosenheim NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced epithelial neoplasms. Ann Int Med 111: 273\u2013279, 1989","journal-title":"Ann Int Med"},{"key":"133993_CR2","first-page":"156","volume":"9","author":"T Thigpen","year":"1990","unstructured":"Thigpen T, Blessing J, Ball H, Hummel S, Barret R: Phase 2 trial of Taxol as a second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group Study (Abstract). Proc Amer Soc Clin Oncol 9: 156, 1990","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"133993_CR3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1073\/pnas.77.3.1561","volume":"77","author":"PB Schiff","year":"1980","unstructured":"Schiff PB, Horowitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci 77: 1561\u20131565, 1980","journal-title":"Proc Natl Acad Sci"},{"key":"133993_CR4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","volume":"82","author":"EK Rowinsky","year":"1990","unstructured":"Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247\u20131259, 1990","journal-title":"J Natl Cancer Inst"},{"key":"133993_CR5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jlb.52.1.119","volume":"52","author":"C Bogdan","year":"1992","unstructured":"Bogdan C, Ding A: Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52: 119\u2013121, 1992","journal-title":"J Leukoc Biol"},{"key":"133993_CR6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.1987.5.8.1232","volume":"5","author":"PH Wiernik","year":"1987","unstructured":"Wiernik PH, Schwartz EL, Enzig A, et al.: Phase 1 trial of Taxol given as a 24-hr infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 5: 1232\u20131239, 1987b.","journal-title":"J Clin Oncol"},{"key":"133993_CR7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.1992.10.7.1165","volume":"10","author":"G Sarosy","year":"1992","unstructured":"Sarosy G, Kohn E, Stone DA, et al.: Phase 1 study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10: 1165\u20131170, 1992","journal-title":"J Clin Oncol"},{"key":"133993_CR8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.1994.12.2.241","volume":"12","author":"JH Schiller","year":"1994","unstructured":"Schiller JH, Storer B, Tutsch K, et al.: Phase 1 trial of 3-hour infusion of paclitaxel with or without granulocyte colony stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241\u2013248, 1994","journal-title":"J Clin Oncol"},{"key":"133993_CR9","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.1993.11.10.2010","volume":"11","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Chaudry V, Forastiere AA, et al.: Phase 1and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010\u20132020, 1993","journal-title":"J Clin Oncol"},{"key":"133993_CR10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","volume":"35","author":"V Chaudry","year":"1994","unstructured":"Chaudry V, Rowinsky EK, Sartorius SE, et al.: Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: Clinical and electrophysiologic studies. Ann Neurol 35: 304\u2013311, 1994","journal-title":"Ann Neurol"},{"key":"133993_CR11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.33.5.626","volume":"33","author":"JC Arezzo","year":"1983","unstructured":"Arezzo JC, Schaumburg HH, Petersen CA: Rapid screening for peripheral neuropathy: A field study with the Optacon. Neurology 33: 626\u2013629, 1983","journal-title":"Neurology"},{"key":"133993_CR12","first-page":"185","volume":"1","author":"F Bove","year":"1986","unstructured":"Bove F, Litwak MS, Arezzo JC, Baker EL: Quantitative sensory testing in occupational medicine. Semin Occupat Med 1: 185\u2013189, 1986","journal-title":"Semin Occupat Med"},{"key":"133993_CR13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/jnnp.52.4.502","volume":"52","author":"MS Rendell","year":"1989","unstructured":"Rendell MS, Katims JJ, Richter R, Rowland F: A comparison of nerve conduction velocities and current perception thresholds as correlates of clinical severity of diabetic sensory neuropathy. J Neurol Neurosurg Psychiat 52: 502\u2013511, 1989","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"133993_CR14","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/archneur.1992.00530360083022","volume":"49","author":"SJ Gulevich","year":"1992","unstructured":"Gulevich SJ, Kalmijn JA, Thal LJ, et al.: Sensory testing in human immunodeficiency virus type 1 infected men. Arch Neurol 49: 1281\u20131284, 1992","journal-title":"Arch Neurol"},{"key":"133993_CR15","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/mus.880151207","volume":"15","author":"JMT Redmond","year":"1992","unstructured":"Redmond JMT, McKenna MJ, Feingold M, Ahmad BK: Sensory testing versus nerve conduction velocity in diabetic polyneuropathy. Muscle & Nerve 15: 1334\u20131339, 1992","journal-title":"Muscle & Nerve"},{"key":"133993_CR16","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1212\/WNL.43.5.1050","volume":"43","author":"Consensus report from the Peripheral Neuropathy Association","year":"1993","unstructured":"Consensus report from the Peripheral Neuropathy Association: Quantitative sensory testing: A consensus report from the Peripheral Neuropathy Association. Neurology 43: 1050\u20131052, 1993","journal-title":"Neurology"},{"key":"133993_CR17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/brain\/115.3.893","volume":"115","author":"R Verdugo","year":"1992","unstructured":"Verdugo R, Ochoa JL: Quantitative somatosensory thermotest. Brain 115: 893\u2013913, 1992","journal-title":"Brain"},{"key":"133993_CR18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01052900","volume":"21","author":"K Peterson","year":"1994","unstructured":"Peterson K, Forsyth P, Posner JB: Paraneoplastic sensorimotor polyneuropathy in patients with breast cancer. J Neuro-Oncol 21: 159\u2013170, 1994","journal-title":"J Neuro-Oncol"},{"key":"133993_CR19","first-page":"1171","volume":"71","author":"RC Donehower","year":"1987","unstructured":"Donehower RC, Rowinsky EK, Grochow LB, et al.: Phase 1 trial of Taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171\u20131177, 1987","journal-title":"Cancer Treat Rep"},{"key":"133993_CR20","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.1991.9.7.1261","volume":"9","author":"T Brown","year":"1991","unstructured":"Brown T, Havlin K, Weiss G, et al.: A phase 1 trial of Taxol given by a six hour intravenous infusion. J Clin Oncol 9: 1261\u20131267, 1991","journal-title":"J Clin Oncol"},{"issue":"SupplC","key":"133993_CR21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0305-7372(93)90050-2","volume":"19","author":"WW ten Bokkel Huinink","year":"1993","unstructured":"ten Bokkel Huinink WW, Eisenhauer E, Swenerton K: Preliminary evaluation of a multicenter, randomized comparative study of Taxol (paclitaxel) dose and infusion length in platinum treated ovarian cancer. Cancer Treat Rev 19 (Suppl C): 79\u201386, 1993","journal-title":"Cancer Treat Rev"},{"key":"133993_CR22","first-page":"2486","volume":"47","author":"PH Wiernik","year":"1987","unstructured":"Wiernik PH, Schwartz EL, Strauman JJ, et al.: Phase 1 clinical and pharmacokinetic study of Taxol. Cancer Res 47: 2486\u20132493, 1987a","journal-title":"Cancer Res"},{"key":"133993_CR23","first-page":"64","volume":"12","author":"TJ Postma","year":"1993","unstructured":"Postma TJ, Liefting AJM, Heimans JJ, et al.: Neurotoxicity in patients with breast cancer (BC) and ovarian cancer (OV) treated with Taxol (Abstract). Proc Amer Soc Clin Oncol 12: 64, 1993","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"133993_CR24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1986.4.5.762","volume":"4","author":"SS Legha","year":"1986","unstructured":"Legha SS, Tenney DM, Krakoff IR: Phase I study of Taxol using a 5-day intermittent schedule. J Clin Oncol 4: 762\u2013766, 1986","journal-title":"J Clin Oncol"},{"key":"133993_CR25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.1995.13.5.1152","volume":"13","author":"A Seidman","year":"1995","unstructured":"Seidman A, Reichman B, Crown J, et al.: Taxol as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13: 1152\u20131159, 1995","journal-title":"J Clin Oncol"},{"key":"133993_CR26","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1993.11.10.1943","volume":"11","author":"BS Reichman","year":"1991","unstructured":"Reichman BS, Seidman AD, Crown JPA, et al.: Taxol and recombinant human granulocyte colony-stimulating factors as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943\u20131951, 1991","journal-title":"J Clin Oncol"},{"key":"133993_CR27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00194546","volume":"9","author":"AI Einzig","year":"1991","unstructured":"Einzig AI, Hochster H, Wiernik PH, et al.: A phase 2 study of Taxol in metastatic melanoma. Invest New Drugs 9: 59\u201364, 1991a","journal-title":"Invest New Drugs"},{"key":"133993_CR28","first-page":"133","volume":"9","author":"AI Einzig","year":"1991","unstructured":"Einzig AI, Gorowski E, Sasloff J, et al.: Phase 2 trial of Taxol in patients with metastatic renal cell carcinoma. Cancer 9: 133\u2013136, 1991b","journal-title":"Cancer"},{"key":"133993_CR29","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1992.10.11.1748","volume":"10","author":"AI Einzig","year":"1992","unstructured":"Einzig AI, Wiernik PH, Sasloff J: Phase II study and long term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748\u20131753, 1992","journal-title":"J Clin Oncol"},{"key":"133993_CR30","first-page":"293","volume":"11","author":"A Chang","year":"1992","unstructured":"Chang A, Kim K, Glick J, et al.: Phase 2 study of Taxol in patients with stage 4 non-small cell lung cancer: ECOG Results (Abstract). Proc Amer Soc Clin Oncol 11: 293, 1992","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"133993_CR31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/86.1.18","volume":"86","author":"EC Kohn","year":"1994","unstructured":"Kohn EC, Sarosy G, Bicher A, et al.: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18\u201324, 1994","journal-title":"J Natl Cancer Inst"},{"key":"133993_CR32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.6124041","volume":"217","author":"ER Peterson","year":"1982","unstructured":"Peterson ER, Crain SM: Nerve growth factor attenuates neurotoxic effects of Taxol on spinal cord-ganglion explants from fetal mice. Science 217: 377\u2013379, 1982","journal-title":"Science"},{"key":"133993_CR33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ana.410290115","volume":"29","author":"SC Apfel","year":"1991","unstructured":"Apfel SC, Lipton RB, Arrezo JC, et al.: Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29: 87\u201390, 1991","journal-title":"Ann Neurol"},{"key":"133993_CR34","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.1991.9.9.1692","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky EK, Gilbert MR, McGuire WP, et al.: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9: 1692\u20131703, 1991","journal-title":"J Clin Oncol"},{"issue":"8","key":"133993_CR35","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0959-8049(94)90459-6","volume":"30A","author":"JMA van Gerven","year":"1994","unstructured":"van Gerven JMA, Moll JWB, van den Bent MJ, et al.: Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30A: No. 8, 1074\u20131077, 1994","journal-title":"Eur J Cancer"},{"key":"133993_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01324696","volume":"16","author":"JG Kaplan","year":"1993","unstructured":"Kaplan JG, Einzig AI, Schaumburg HH: Taxol causes permanent large fiber peripheral nerve dysfunction: A lesson for preventative strategies. J Neuro-Oncol 16: 105\u2013107, 1993","journal-title":"J Neuro-Oncol"},{"key":"133993_CR37","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","volume":"83","author":"FA Holmes","year":"1991","unstructured":"Holmes FA, Walter RS, Theriault RL, et al.: Phase 2 trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797\u20131805, 1991","journal-title":"J Natl Cancer Inst"},{"key":"133993_CR38","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","volume":"11","author":"EL Trimble","year":"1993","unstructured":"Trimble EL, Adams JD, Vena D, Hawkins MJ, et al.: Taxol for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11: 2405\u20132410, 1993","journal-title":"J Clin Oncol"},{"key":"133993_CR39","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.39.3.368","volume":"39","author":"RB Lipton","year":"1989","unstructured":"Lipton RB, Apfel SC, Dutcher JP, et al.: Taxol produces a predominantly sensory neuropathy. Neurology 39: 368\u2013373, 1989","journal-title":"Neurology"},{"key":"133993_CR40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archneur.1994.00540190110024","volume":"51","author":"Z Sahenk","year":"1994","unstructured":"Sahenk Z, Barohn R, New P, et al.: Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51: 726\u2013729, 1994","journal-title":"Arch Neurol"},{"issue":"SupplC","key":"133993_CR41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0305-7372(93)90049-W","volume":"19","author":"RC Donehower","year":"1993","unstructured":"Donehower RC, Rowinsky EK: An overview of experience with Taxol (paclitaxel) in the USA. Cancer Treat Rev 19 (Suppl C): 63\u201378, 1993","journal-title":"Cancer Treat Rev"},{"key":"133993_CR42","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.1994.12.8.1741","volume":"12","author":"AD Seidman","year":"1994","unstructured":"Seidman AD, Barrett S, Canezo S: Photopsia during 3-hour Taxol administration at doses ??250 mg\/M2. J Clin Oncol 12: 1741\u20131742, 1994","journal-title":"J Clin Oncol"},{"key":"133993_CR43","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/jnci\/86.14.1099","volume":"86","author":"E Capri","year":"1994","unstructured":"Capri E, Munzone E, Tarenzi, Fulfaro, Gianni L: Optic nerve disturbances: A new form of paclitaxel neurotoxicity. J Natl Cancer Inst 86: 1099\u20131101, 1994","journal-title":"J Natl Cancer Inst"},{"key":"133993_CR44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19900915)66:6<1117::AID-CNCR2820660607>3.0.CO;2-O","volume":"66","author":"T Siegal","year":"1990","unstructured":"Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66: 1117\u20131123, 1990","journal-title":"Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005805907311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005805907311\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005805907311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T08:33:56Z","timestamp":1749630836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005805907311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,10]]}},"alternative-id":["133993"],"URL":"https:\/\/doi.org\/10.1023\/a:1005805907311","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,10]]}}}